Tradestie Institutional Equity Comparison Engine

VCYT vs CDNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CDNA Overall Edge

CDNA Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CareDx, Inc. (CDNA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while VCYT counters with relative strength in Valuation. Fundamentally, VCYT trades at 15.3x Forward P/E with 15.0% operating margin (+15.1% YoY revenue) versus CDNA at 47.1x Forward P/E and 1.6% operating margin (+39.3% YoY). In options structure, VCYT sits in BREAKDOWN (47th %ile IV; Dealer Gamma Walls on Pro) against CDNA sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner VCYT
VCYT 15.3x vs CDNA 47.1x Fwd P/E
Growth & Margin Winner CDNA
Op Margin 15.0% vs 1.6% ยท YoY +15.1% vs +39.3%
Momentum & Technical Winner CDNA
1Y -39.8% vs +364.5% ยท 52W Pos 5% vs 77%
Options & Structure Winner CDNA
BREAKDOWN (47th %ile IV) vs CONSOLIDATION (18th %ile IV)
VCYT NASDAQ
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
1M Return -44.32%
1Y Return -39.78%
Forward P/E 15.3x
Unified AI Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
CDNA NASDAQ
CareDx, Inc.
Services-Medical Laboratories
$73.72
-5.34% 1D
Market Cap $4.1B
1M Return +15.19%
1Y Return +364.52%
Forward P/E 47.1x
Unified AI Score
24.5 / 100 STRONG SELL
Tech 15.0 Fund 36.0 Flow 70.0 Mom 25.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VCYT -39.78% CDNA +364.52% Spread: +404.3 pp (CDNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period VCYT Revenue CDNA Revenue VCYT Op. Margin CDNA Op. Margin Margin Edge
FY2018 $90M $80M -24.2% -20.3% CDNA
FY2019 $120M $130M -12.6% -19.3% VCYT
FY2020 $120M $190M -30.1% -11.7% CDNA
FY2021 $220M $300M -37.3% -10.0% CDNA
FY2022 $300M $320M -13.9% -24.0% VCYT
FY2023 $360M $280M -23.8% -72.5% VCYT
FY2024 $450M $330M 3.6% 12.2% CDNA
FY2025 $520M $380M 11.2% -8.1% VCYT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VCYT (4) vs CDNA (6)
Institutional Metric VCYT CDNA Criterion Row Winner
Market Capitalization Scale $2.0B $4.1B Larger Scale CDNA
Trailing P/E Ratio Valuation 15.8x 32.9x Lower Multiple VCYT
Forward P/E Ratio Valuation 15.3x 47.1x Lower Multiple VCYT
Revenue Growth (YoY) Growth +15.1% +39.3% Higher Growth CDNA
Operating Margin (TTM) Profitability 15.0% 1.6% Higher Margin VCYT
Net Profit Margin Profitability 21.8% 25.9% Higher Margin CDNA
Return on Equity (ROE) Capital Efficiency 9.4% 33.0% Higher ROE CDNA
52-Week Range Position Momentum 5% ($22โ€“$61) 77% ($15โ€“$91) Stronger Trend CDNA
Beta / 30D Volatility Risk Regime 3.01ฮฒ ยท 199% Vol 1.21ฮฒ ยท 98% Vol Lower Realized Risk CDNA
Unified Institutional Score Composite Signal 49.1 / 100 (HOLD) 24.5 / 100 (STRONG SELL) Higher Composite VCYT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VCYT vs CDNA Buy Guide
VCYT BREAKDOWN
99d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 47th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live VCYT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CDNA CONSOLIDATION
30d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 18th %ile
IV Regime Compressed (<25th %ile)
Live CDNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VCYT nor CDNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.